@article {909,
	title = {Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study},
	journal = {Scientific Reports},
	volume = {11},
	year = {2021},
	pages = {3846},
	abstract = {<p>To date, two randomized, controlled studies support the use of candesartan for migraine prophylaxis but with limited external validity. We aim to evaluate the effectiveness and tolerability of candesartan in clinical practice and to explore predictors of patient response. Retrospective cohort study including all patients with migraine who received candesartan between April 2008-February 2019. The primary endpoint was the number of monthly headache days during weeks 8{\textendash}12 of treatment compared to baseline. Additionally, we evaluated the frequency during weeks 20{\textendash}24. We analysed the percentage of patients with 50\% and 75\% response rates and the retention rates after three and 6\&nbsp;months of treatment. 120/4121 patients were eligible, aged 45.9 [11.5]; 100 (83.3\%) female. Eighty-four patients (70\%) had chronic migraine and 53 (42.7\%) had medication-overuse headache. The median number of prior prophylactics was 3 (Inter-quartile range 2{\textendash}5). At baseline, patients had 20.5 {\textpm} 8.5 headache days per month, decreasing 4.3 {\textpm} 8.4\&nbsp;days by 3\&nbsp;months (weeks 12{\textendash}16) and by 4.7 {\textpm} 8.7\&nbsp;days by 6\&nbsp;months (paired Student{\textquoteright}s t-test, p \&lt; 0.001). The percentage of patients with a 50\% response was 32.5\% at 3\&nbsp;months and 31.7\% at 6\&nbsp;months, while the retention rate was 85.0\% and 58.3\%. The number of prior treatments (Odds ratio 0.79, 95\% CI 0.64{\textendash}0.97) and the presence of daily headache (Odds ratio 0.39, 95\% CI 0.16{\textendash}0.97) were associated with a lower probability of response. Candesartan showed beneficial effects in the preventive treatment of migraine in clinical practice, including patients with chronic migraine, medication-overuse headache and resistance to prior prophylactics.</p>
},
	issn = {2045-2322},
	doi = {10.1038/s41598-021-83508-2},
	url = {https://doi.org/10.1038/s41598-021-83508-2},
	author = {S{\'a}nchez-Rodr{\'\i}guez, Carmen and Sierra, {\'A}lvaro and {\'A}lvaro Planchuelo-G{\'o}mez and Mart{\'\i}nez-P{\'\i}as, Enrique and {\'A}ngel L. Guerrero and Garc{\'\i}a-Azor{\'\i}n, David}
}
@article {887,
	title = {Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study},
	journal = {The Journal of Headache and Pain},
	volume = {21},
	year = {2020},
	month = {Jul},
	pages = {94},
	abstract = {Headache is one of the most frequent neurologic manifestations in COVID-19. We aimed to analyze which symptoms and laboratory abnormalities were associated with the presence of headache and to evaluate if patients with headache had a higher adjusted in-hospital risk of mortality.},
	issn = {1129-2377},
	doi = {10.1186/s10194-020-01165-8},
	url = {https://doi.org/10.1186/s10194-020-01165-8},
	author = {Trigo, Javier and Garc{\'\i}a-Azor{\'\i}n, David and {\'A}lvaro Planchuelo-G{\'o}mez and Mart{\'\i}nez-P{\'\i}as, Enrique and Talavera, Blanca and Hern{\'a}ndez-P{\'e}rez, Isabel and Valle-Pe{\~n}acoba, Gonzalo and Sim{\'o}n-Campo, Paula and de Lera, Mercedes and Chavarr{\'\i}a-Miranda, Alba and L{\'o}pez-Sanz, Cristina and Guti{\'e}rrez-S{\'a}nchez, Mar{\'\i}a and Mart{\'\i}nez-Velasco, Elena and Pedraza, Mar{\'\i}a and Sierra, {\'A}lvaro and G{\'o}mez-Vicente, Beatriz and Juan F Arenillas and {\'A}ngel L. Guerrero}
}
